Patients who responded to anti–PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria.
Jennifer Wargo, MD
Advertisement
Articles by Jennifer Wargo, MD
In this interview we discuss the effect of the gut microbiome on responses and survival outcomes in metastatic melanoma patients treated with anti–PD-1 immunotherapies.
Advertisement
Latest Updated Articles
Role of Gut Microbiome in Metastatic Melanoma Patients on ImmunotherapyPublished: June 27th 2017 | Updated:
Determining the Role of the Gut Microbiome in Melanoma Treated With Anti–PD-1 ICIsPublished: June 6th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
